{
    "clinical_study": {
        "@rank": "146326", 
        "arm_group": {
            "arm_group_label": "LEO 90100", 
            "arm_group_type": "Experimental", 
            "description": "Not applicable"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the pharmacodynamic activity of LEO 90100 with\n      Dermovate\u00ae cream, Dovobet\u00ae ointment, betamethasone dipropionate in LEO90100 vehicle,\n      Synalar\u00ae ointment and LEO 90100 vehicle using a human skin blanching test."
        }, 
        "brief_title": "A Vasoconstriction Study With LEO 90100", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Psoriasis Vulgaris", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Following verbal and written information about the trial, the subject must provide\n             signed and dated informed consent before any study related activities are carried\n             out.\n\n          -  Healthy male or female volunteers, 18 to 50 years old, both inclusive\n\n        Exclusion Criteria:\n\n          -  Female subjects who are pregnant or who are breast feeding.\n\n          -  Abnormal pigmentation of the skin or skin type that could, in any way, confound\n             interpretation of the study results (skin type V and VI on the Fitzpatrick scale)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946386", 
            "org_study_id": "LP0053-69"
        }, 
        "intervention": [
            {
                "arm_group_label": "LEO 90100", 
                "description": "The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours", 
                "intervention_name": "LEO 90100 Aerosol, foam", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LEO 90100", 
                "intervention_name": "Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LEO 90100", 
                "intervention_name": "LEO 90100 Aerosol, foam, vehicle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LEO 90100", 
                "intervention_name": "Daivobet\u00ae ointment", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LEO 90100", 
                "intervention_name": "Dermovate\u00ae cream", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LEO 90100", 
                "intervention_name": "Synalar\u00ae ointment", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Betamethasone-17,21-dipropionate", 
                "Betamethasone", 
                "Clobetasol", 
                "Fluocinolone Acetonide", 
                "Betamethasone sodium phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nice", 
                    "country": "France", 
                    "zip": "06202"
                }, 
                "name": "CPCAD, Centre de Pharmacologie Clinique Appliqu\u00e9e \u00e0 la Dermatologie"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: ANSM - Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicaments et des Produits de Sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Visual Assessment of Skin Blanching on scores 0 to 4", 
            "measure": "Visual assessment of skin blanching (visual score (VS))", 
            "safety_issue": "No", 
            "time_frame": "06:10, 08:00, 10:00, 12:00, 24:00, 28:00 and 32:00 hours after application"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946386"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from baseline in colorimetric parameter. AUC (0-32h) of this change by treatment site will be calculated after subtraction of untreated site change", 
                "measure": "Change from baseline in colorimetric parameter a* (the red/green balance) at each time point", 
                "safety_issue": "No", 
                "time_frame": "06:10, 08:00, 10:00, 12:00, 24:00, 28:00 and 32:00 hours after application"
            }, 
            {
                "description": "AUC (0-32h) of this change by treatment site will be calculated after subtraction of untreated site change", 
                "measure": "Change from baseline in colorimetric parameter L* (luminance) at each time point (\u0394L*)", 
                "safety_issue": "No", 
                "time_frame": "06:10, 08:00, 10:00, 12:00, 24:00, 28:00 and 32:00 hours after application"
            }
        ], 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}